Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Runswick

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Respirology (Carlton, Vic.)|November 8, 2007
Pollen proteolytic enzymes degrade tight junctionsSarah Runswick, Thomas Mitchell, Paul Davies, et al.
The New England Journal of Medicine|June 6, 2017
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationMark Robson, Seock-Ah Im, Elżbieta Senkus, et al.
BMC Medical Genomics|January 1, 2013
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell linesAndreas Schlicker, Garry Beran, Christine M Chresta, et al.
Cancer Research|January 25, 2012
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)Sarah V Holt, Armelle Logie, Barry R Davies, et al.
Plos One|July 11, 2013
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibJames R Bradford, Matthew Farren, Steve J Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2024
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell ResponsesAnna Morena D'Alise, Guido Leoni, Gabriella Cotugno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Cancer Research|March 11, 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry, Sandra Pavey, Christine A Pratilas, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Respirology (Carlton, Vic.)|November 8, 2007
Pollen proteolytic enzymes degrade tight junctionsSarah Runswick, Thomas Mitchell, Paul Davies, et al.
The New England Journal of Medicine|June 6, 2017
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationMark Robson, Seock-Ah Im, Elżbieta Senkus, et al.
BMC Medical Genomics|January 1, 2013
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell linesAndreas Schlicker, Garry Beran, Christine M Chresta, et al.
Cancer Research|January 25, 2012
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)Sarah V Holt, Armelle Logie, Barry R Davies, et al.
Plos One|July 11, 2013
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibJames R Bradford, Matthew Farren, Steve J Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2024
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell ResponsesAnna Morena D'Alise, Guido Leoni, Gabriella Cotugno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Cancer Research|March 11, 2010
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry, Sandra Pavey, Christine A Pratilas, et al.
Pageof 1